RxDoctor Payments Data

Dana Johnson, NP

Adult Health · Mobile, ALNPI 1619289915

Payments from drug & device makers

$2,819in general payments, 2019–2025

Across 171 payments — averaging $16.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$439
  • Ironwood Pharmaceuticals, Inc$170
  • Merck$139
  • Novo Nordisk$122
  • Regeneron Healthcare Solutions, Inc.$111
  • plus $599 from 15 others

What the payments were for

  • Food & beverage$2,819100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,819 in reported general payments places this provider in the 80th percentile of 308 adult health providers in Alabama.

See all adult health providers in Alabama

Medicare billing

Part B allowed, 2024
$22,574
Medicare patients
174
Services billed
387

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide101$71,919
CreonLipase/Protease/Amylase25$53,563
Dexlansoprazole DrDexlansoprazole47$14,087
Famotidine784$12,664
Mesalamine54$12,202
Sucralfate354$9,372
Dicyclomine Hcl391$8,907
Pantoprazole Sodium590$7,509
Budesonide DrBudesonide45$7,277
Budesonide EcBudesonide15$4,944
Mesalamine ErMesalamine19$3,194
Glycopyrrolate61$2,103
Esomeprazole Magnesium30$1,910
Colestipol Hcl26$1,492
Lubiprostone15$1,483

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Creon$1,239$125,482126 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 308 adult health providers in Alabama.

Other adult health in Mobile

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →